Health and Medicine Wiki
Register
Advertisement

{{drugbox |drug = Vortioxetine |tradenames = Brintellix |synonyms = Lu-AA21004 |size = 200 |ChemSpider = 8141643 |DrugBank = None |PubChem = 9966051 |formula = C18H22N2S |Mass = 298.4457 g/mol |InChl = 1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3 |InChl-key = YQNWZWMKLDQSAC-UHFFFAOYSA-N |SMILES = CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C |jmol = http://chemapps.stolaf.edu/jmol/jmol.php?model=CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C |IUPAC = 1-{2-[(2,4-Dimethylphenyl)sulfanyl]phenyl}piperazine }}

Vortioxetine is a multi-modal antidepressant that is solely approved for clinical use in the U.S.; it first received FDA approval in 30 September 2013.[1]

External links[]

Reference list[]

  1. Alvarez, E; Perez, V; Artigas, F (July 2014). "Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder.". Neuropsychiatric Disease and Treatment 10: 1297–307. PMC 4106971. PMID 25075188. doi:10.2147/NDT.S41387. 
Advertisement